| Literature DB >> 26306765 |
Theoharis C Theoharides1, Irene Tsilioni2, Lauren Arbetman2, Smaro Panagiotidou2, Julia M Stewart2, Rae M Gleason2, Irwin J Russell2.
Abstract
Fibromyalgia syndrome (FMS) is a chronic, idiopathic condition of widespread musculoskeletal pain, affecting primarily women. It is clinically characterized by chronic, nonarticular pain and a heightened response to pressure along with sleep disturbances, fatigue, bowel and bladder abnormalities, and cognitive dysfunction. The diagnostic criteria have changed repeatedly, and there is neither a definitive pathogenesis nor reliable diagnostic or prognostic biomarkers. Clinical and laboratory studies have provided evidence of altered central pain pathways. Recent evidence suggests the involvement of neuroinflammation with stress peptides triggering the release of neurosenzitizing mediators. The management of FMS requires a multidimensional approach including patient education, behavioral therapy, exercise, and pain management. Here we review recent data on the pathogenesis and propose new directions for research and treatment.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26306765 PMCID: PMC4613957 DOI: 10.1124/jpet.115.227298
Source DB: PubMed Journal: J Pharmacol Exp Ther ISSN: 0022-3565 Impact factor: 4.030